NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study Novo's Phase 3 CagriSema results disappoint analysts, sending stock tumbling MM+M Medical Marketing and Media Pharmacy Phase III REDEFINE trials at #ADA2025 reveal that once weekly CagriSema (semaglutide + cagrilintide) delivers impressive weight loss in adults without diabetes and in those with type 2 #diabetes, alongside favorable CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension